Display options
Cite
Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;9:CD011440doi: 10.1002/14651858.CD011440.pub2.
Petsky, H. L., Kew, K. M., Turner, C., & Chang, A. B. (2016). Exhaled nitric oxide levels to guide treatment for adults with asthma. The Cochrane database of systematic reviews, 9CD011440. https://doi.org/10.1002/14651858.CD011440.pub2
Petsky, Helen L, et al. "Exhaled nitric oxide levels to guide treatment for adults with asthma." The Cochrane database of systematic reviews vol. 9 (2016): CD011440. doi: https://doi.org/10.1002/14651858.CD011440.pub2
Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016 Sep 01;9:CD011440. doi: 10.1002/14651858.CD011440.pub2. PMID: 27580628; PMCID: PMC6457753.
Copy Download .nbib Format: NLM
Share it on

Cochrane Database Syst Rev. 2016 Sep 01;9:CD011440. doi: 10.1002/14651858.CD011440.pub2.

Exhaled nitric oxide levels to guide treatment for adults with asthma.

The Cochrane database of systematic reviews

Helen L Petsky, Kayleigh M Kew, Cathy Turner, Anne B Chang

Affiliations

  1. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.

PMID: 27580628 PMCID: PMC6457753 DOI: 10.1002/14651858.CD011440.pub2

Abstract

BACKGROUND: Asthma guidelines aim to guide health practitioners to optimise treatment for patients so as to minimise symptoms, improve or maintain good lung function, and prevent acute exacerbations or flare-ups. The principle of asthma guidelines is based on a step-up or step-down regimen of asthma medications to maximise good health outcomes using minimum medications. Asthma maintenance therapies reduce airway inflammation that is usually eosinophilic. Tailoring asthma medications in accordance with airway eosinophilic levels may improve asthma outcomes such as indices of control or reduce exacerbations or both. Fractional exhaled nitric oxide (FeNO) is a marker of eosinophilic inflammation, and as it is easy to measure, has an advantage over other measurements of eosinophilic inflammation (for example sputum eosinophils).

OBJECTIVES: To evaluate the efficacy of tailoring asthma interventions based on exhaled nitric oxide (FeNO), in comparison to not using FeNO, that is management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines or both, for asthma-related outcomes in adults.

SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and reference lists of articles. The last searches were undertaken in June 2016.

SELECTION CRITERIA: All randomised controlled trials (RCTs) comparing adjustment of asthma medications based on exhaled nitric oxide levels compared to not using FeNO, that is management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines or both.

DATA COLLECTION AND ANALYSIS: We reviewed results of searches against predetermined criteria for inclusion. We independently selected relevant studies in duplicate. Two review authors independently assessed trial quality and extracted data. We contacted study authors for further information, receiving responses from four.

MAIN RESULTS: We included seven adult studies; these studies differed in a variety of ways including definition of asthma exacerbations, FeNO cutoff levels used (15 to 35 ppb), the way in which FeNO was used to adjust therapy, and duration of study (4 to 12 months). Of 1700 randomised participants, 1546 completed the trials. The mean ages of the participants ranged from 28 to 54 years old. The inclusion criteria for the participants in each study varied, but all had a diagnosis of asthma and required asthma medications. In the meta-analysis, there was a significant difference in the primary outcome of asthma exacerbations between the groups, favouring the FeNO group. The number of people having one or more asthma exacerbations was significantly lower in the FeNO group compared to the control group (odds ratio (OR) 0.60, 95% confidence interval (CI) 0.43 to 0.84). The number needed to treat to benefit (NNTB) over 52 weeks was 12 (95% CI 8 to 32). Those in the FeNO group were also significantly more likely to have a lower exacerbation rate than the controls (rate ratio 0.59, 95% CI 0.45 to 0.77). However, we did not find a difference between the groups for exacerbations requiring hospitalisation (OR 0.14, 95% CI 0.01 to 2.67) or rescue oral corticosteroids (OR 0.86, 95% CI 0.50 to 1.48). There was also no significant difference between groups for any of the secondary outcomes (FEV

AUTHORS' CONCLUSIONS: With new studies included since the last version of this review, which included adults and children, this updated meta-analysis in adults with asthma showed that tailoring asthma medications based on FeNO levels (compared with primarily on clinical symptoms) decreased the frequency of asthma exacerbations but did not impact on day-to-day clinical symptoms, end-of-study FeNO levels, or inhaled corticosteroid dose. Thus, the universal use of FeNO to help guide therapy in adults with asthma cannot be advocated. As the main benefit shown in the studies in this review was a reduction in asthma exacerbations, the intervention may be most useful in adults who have frequent exacerbations. Further RCTs encompassing different asthma severity, ethnic groups in less affluent settings, and taking into account different FeNO cutoffs are required.

References

  1. Chest. 2006 Jun;129(6):1492-9 - PubMed
  2. Eur Respir J. 2002 Sep;20(3):601-8 - PubMed
  3. J Asthma. 2015;52(10):1013-9 - PubMed
  4. Am J Respir Crit Care Med. 2005 Oct 1;172(7):831-6 - PubMed
  5. J Asthma. 2015;52(10):1023-30 - PubMed
  6. Med Hypotheses. 2016 Jun;91:20-23 - PubMed
  7. Pediatr Pulmonol. 2014 Jul;49(7):624-31 - PubMed
  8. Eur Respir J. 2016 Mar;47(3):751-68 - PubMed
  9. Clin Respir J. 2013 Apr;7(2):204-13 - PubMed
  10. Chest. 2008 Oct;134(4):733-9 - PubMed
  11. Am J Respir Crit Care Med. 2009 Jan 15;179(2):93-7 - PubMed
  12. Thorax. 2011 Jun;66(6):514-20 - PubMed
  13. Eur J Med Res. 2000 Aug 18;5(8):334-40 - PubMed
  14. J Allergy Clin Immunol. 2009 Aug;124(2):213-21, 221.e1 - PubMed
  15. J Allergy (Cairo). 2010;2010: - PubMed
  16. Pediatr Pulmonol. 2006 Sep;41(9):855-62 - PubMed
  17. Lancet. 2008 Sep 20;372(9643):1065-72 - PubMed
  18. JAMA. 2012 Sep 12;308(10):987-97 - PubMed
  19. Thorax. 1999 Feb;54(2):108-14 - PubMed
  20. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30 - PubMed
  21. Medicine (Baltimore). 2015 Jan;94(4):e347 - PubMed
  22. Eur Respir J. 1996 Feb;9(2):196-201 - PubMed
  23. Chest. 2012 Dec;142(6):1553-1561 - PubMed
  24. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006340 - PubMed
  25. Pediatr Pulmonol. 2015 Jun;50(6):535-43 - PubMed
  26. Pediatr Pulmonol. 2016 Mar;51(3):316-28 - PubMed
  27. Lancet. 2011 Sep 10;378(9795):983-90 - PubMed
  28. J Allergy Clin Immunol. 2015 Mar;135(3):682-8.e11 - PubMed
  29. Am J Respir Crit Care Med. 2007 Aug 1;176(3):231-7 - PubMed
  30. J Allergy Clin Immunol. 2001 Jan;107(1):3-8 - PubMed
  31. Health Technol Assess. 2015 Oct;19(82):1-330 - PubMed
  32. J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):639-48.e1-8 - PubMed
  33. Thorax. 2002 Jul;57(7):643-8 - PubMed
  34. Respir Med. 2005 May;99(5):631-7 - PubMed
  35. Br Med Bull. 2000;56(4):985-1003 - PubMed
  36. Thorax. 1998 Feb;53(2):91-5 - PubMed
  37. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):894-8 - PubMed
  38. Thorax. 2015 Jun;70(6):543-50 - PubMed
  39. N Engl J Med. 2005 May 26;352(21):2163-73 - PubMed
  40. Thorax. 2002 Oct;57(10):889-96 - PubMed
  41. Am J Respir Crit Care Med. 2001 Sep 1;164(5):738-43 - PubMed
  42. Am J Respir Crit Care Med. 2005 May 15;171(10):1077-82 - PubMed

Publication Types

Grant support